All Stories

  1. Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder

    Article • October 2018, Dove Medical Press

    Dr Raymond W Lam, Mr Aaron Yarlas

  2. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey

    Article • Journal of Crohn s and Colitis, February 2018, Oxford University Press (OUP)

    Mr Aaron Yarlas

  3. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study

    Article • Inflammatory Bowel Diseases, January 2018, Oxford University Press (OUP)

    Mr Aaron Yarlas

  4. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

    Article • Journal of Patient-Reported Outcomes, December 2017, Springer Science + Business Media

    Mr Aaron Yarlas

  5. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies

    Article • Journal of Crohn s and Colitis, September 2017, Oxford University Press (OUP)

    Mr Aaron Yarlas

  6. Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review

    Article • Quality of Life Research, August 2017, Springer Science + Business Media

    Mr Aaron Yarlas

  7. A Systematic Review of the SF-36® Health Survey for Measuring Health-Related Quality of Life in Patients with Ulcerative Colitis

    Article • Gastroenterology, April 2017, Elsevier

    Mr Aaron Yarlas

  8. The SF-36® Health Survey Distinguishes Disease Burden on Functioning and Well-Being Between Patients with Active vs Inactive Ulcerative Colitis

    Article • Gastroenterology, April 2017, Elsevier

    Mr Aaron Yarlas

  9. P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis

    Article • Journal of Crohn s and Colitis, January 2017, Oxford University Press (OUP)

    Mr Aaron Yarlas

  10. A Systematic Review of The SF-36® Health Survey for Measuring Health-Related Quality of Life In Patients with Ulcerative Colitis

    Article • Value in Health, November 2016, Elsevier

    Mr Aaron Yarlas

  11. COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN’S DISEASE PATIENTS

    Article • Value in Health, May 2016, Elsevier

    Mr Aaron Yarlas

  12. Su1014 Evidence of Content Validity and Psychometric Properties of Sf-36 for Measuring Health-Related Quality of Life of Patients With Crohn's Disease

    Article • Gastroenterology, April 2016, Elsevier

    Mr Aaron Yarlas

  13. Measuring Generic Health-Related Quality Of Life And Impact Of Health Resource Utilization In Adults With Cystic Fibrosis

    Article • Value in Health, November 2015, Elsevier

    Mr Aaron Yarlas

  14. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression

    Article • Pain Practice, April 2015, Wiley

    Mr Aaron Yarlas

  15. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate‐to‐Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials

    Article • Pain Practice, January 2015, Wiley

    Mr Aaron Yarlas

  16. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain

    Article • Postgraduate Medicine, December 2014, Taylor & Francis

    Mr Aaron Yarlas

  17. P-107 Health-Related Quality of Life in Patients with Ulcerative Colitis Receiving Short- And Long-Term Treatment with Multimatrix Mesalamine

    Article • Inflammatory Bowel Diseases, December 2014, Wolters Kluwer Health

    Mr Aaron Yarlas

  18. The Impact of Buprenorphine Transdermal Delivery System on Activities of Daily Living Among Patients With Chronic Low Back Pain

    Article • Clinical Journal of Pain, December 2014, Wolters Kluwer Health

    Mr Aaron Yarlas

  19. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX® formulated delayed-release mesalamine

    Article • Quality of Life Research, September 2014, Springer Science + Business Media

    Mr Aaron Yarlas

  20. The correspondence between patient-reported outcome (PRO) instruments and measures of disease activity in adult patients with mild-to-moderate ulcerative colitis (UC) receiving short-term daily treatment with mmx mesalamine

    Article • Value in Health, May 2014, Elsevier

    Mr Aaron Yarlas

  21. Standardization of mental health assessment – using item response theory (IRT) to cross-calibrate two self-reported mental health tools: The patient health questionnaire (PHQ-9) and the SF-36v2 mental health (MH) scale

    Article • Value in Health, May 2014, Elsevier

    Mr Aaron Yarlas

  22. P514 Disease-specific health-related quality of life in adult patients with mild to moderate ulcerative colitis receiving short-term and long-term daily treatment with MMX mesalazine

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    Mr Aaron Yarlas

  23. P456 Impact of short-term and long-term daily therapy with MMX mesalazine on work-related outcomes in patients with mild-to-moderate ulcerative colitis

    Article • Journal of Crohn s and Colitis, February 2014, Oxford University Press (OUP)

    Mr Aaron Yarlas

  24. The development and validation of a revised version of the medical outcomes study cognitive functioning scale (MOS-COG-R)

    Article • Value in Health, May 2013, Elsevier

    Mr Aaron Yarlas

  25. Responsiveness among patient-reported measures of quality of life, quality of sleep, and functional disability to pain and impact of buprenorphine transdermal system (BTDS) treatment in chronic low back pain patients

    Article • Value in Health, May 2013, Elsevier

    Mr Aaron Yarlas

  26. Correlates of improvement in physical quality of life and quality of sleep among chronic low back pain patients with treatment with buprenorphine transdermal system (BTDS)

    Article • Value in Health, May 2013, Elsevier

    Mr Aaron Yarlas

  27. Does depression status impact treatment effectiveness for chronic low back pain?

    Article • Journal of Pain, April 2013, Elsevier

    Mr Aaron Yarlas

  28. Long-term maintenance of improvements in patient-reported functioning, quality-of-life, and pain outcomes for moderate-to-severe chronic pain patients receiving continuous treatment of Butrans® (buprenorphine) Transdermal System (BTDS)

    Article • Journal of Pain, April 2013, Elsevier

    Mr Aaron Yarlas

  29. Commentary on “A new indicator for the measurement of change with ordinal scores”

    Article • Quality of Life Research, February 2013, Springer Science + Business Media

    Mr Aaron Yarlas

  30. Impact of MMX® Mesalamine on Improvement and Maintenance of Health-Related Quality of Life in Patients with Ulcerative Colitis

    Article • Inflammatory Bowel Diseases, February 2013, Wolters Kluwer Health

    Mr Aaron Yarlas

  31. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain

    Article • Expert Opinion on Pharmacotherapy, February 2013, Informa Healthcare

    Mr Aaron Yarlas

  32. A Randomized, Placebo-Controlled Study of the Impact of the 7-Day Buprenorphine Transdermal System on Health-Related Quality of Life in Opioid-Naïve Patients With Moderate-to-Severe Chronic Low Back Pain

    Article • Journal of Pain, January 2013, Elsevier

    Mr Aaron Yarlas

  33. QU1 The Development and Validation of a Revised Version of the Medical Outcomes Study Sleep Scale (MOS-Sleep-R)

    Article • Value in Health, June 2012, Elsevier

    Mr Aaron Yarlas

  34. PSY6 The Impact on Sleep Quality of Butrans® (Buprenorphine) Transdermal System 5 Mcg/Hour (BTDS 5) and 20 Mcg/Hour (BTDS 20) Dosages in Patients With Moderate-to-Severe Chronic Low Back Pain

    Article • Value in Health, June 2012, Elsevier

    Mr Aaron Yarlas

  35. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients

    Article • Alimentary Pharmacology & Therapeutics, April 2012, Wiley

    Mr Aaron Yarlas

  36. PGI28 Disease-Specific Health-related Quality of Life in Patients with Quiescent Ulcerative Colitis: Effects of one Year Maintenance Treatment with MMX Mesalamine

    Article • Value in Health, November 2011, Elsevier

    Mr Aaron Yarlas

  37. PGI31 The Maintenance of Work-related Productivity During One Year of MMX Mesalamine Treatment for Patients with Quiescent Ulcerative Colitis

    Article • Value in Health, November 2011, Elsevier

    Mr Aaron Yarlas

  38. PGI22 CONCORDANCE AMONG MULTIPLE HEALTH OUTCOMES MEASURES IN RESPONSIVENESS TO MULTI-MATRIX MESALAMINE MAINTENANCE TREATMENT FOR PATIENTS WITH QUIESCENT ULCERATIVE COLITIS

    Article • Value in Health, May 2011, Elsevier

    Mr Aaron Yarlas

  39. PGI21 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS BEFORE AND AFTER 8 WEEKS' TREATMENT WITH MULTI-MATRIX MESALAMINE: COMPARISON WITH 2009 GENERAL POPULATION NORMS IN THE UNITED STATES

    Article • Value in Health, May 2011, Elsevier

    Mr Aaron Yarlas

  40. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

    Article • Haemophilia, February 2011, Wiley

    Mr Aaron Yarlas

  41. Measuring the health status burden in hemodialysis patients using the SF-36® health survey

    Article • Quality of Life Research, October 2010, Springer Science + Business Media

    Mr Aaron Yarlas

  42. PGI32 CORRESPONDENCE OF MULTIPLE HEALTH OUTCOMES MEASURES IN RESPONSIVENESS TO MMX™ MESALAMINE TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS

    Article • Value in Health, May 2010, Elsevier

    Mr Aaron Yarlas

  43. M1040 Improvement in Health-Related Quality of Life Following Treatment With MMX® Mesalamine in Patients With Ulcerative Colitis

    Article • Gastroenterology, May 2010, Elsevier

    Mr Aaron Yarlas

  44. M1041 The Impact of MMX® Mesalamine Treatment on the Disease-Specific Health-Related Quality of Life of Patients With Ulcerative Colitis

    Article • Gastroenterology, May 2010, Elsevier

    Mr Aaron Yarlas

  45. The minimally important difference of the Asthma Control Test

    Article • Journal of Allergy and Clinical Immunology, October 2009, Elsevier

    Mr Aaron Yarlas

  46. PIH39 ASSOCIATION BETWEEN SEXUAL DRIVE CHANGE AND PREMENSTRUAL SYMPTOMS

    Article • Value in Health, May 2009, Elsevier

    Mr Aaron Yarlas

  47. PIH33 LONGITUDINAL VALIDATION OF THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY (PMSIS)

    Article • Value in Health, May 2009, Elsevier

    Mr Aaron Yarlas

  48. PIH40 ASSESSING WORK PRODUCTIVITY IMPAIRMENT IN PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHRORIC DISORDER

    Article • Value in Health, May 2009, Elsevier

    Mr Aaron Yarlas

  49. MS2 COMBINING THE SF—36 PHYSICAL FUNCTION SCALE AND THE HEALTH ASSESSMENT QUESTIONNAIRE TO IMPROVE MEASUREMENT OF PHYSICAL FUNCTION RHEUMATOID ARTHRITIS (RA): RESULTS: FROM THE PREMIER STUDY

    Article • Value in Health, May 2009, Elsevier

    Mr Aaron Yarlas

  50. The Minimally Important Difference (MID) of the Asthma Control Test (ACT) Administered by Telephone

    Article • Journal of Allergy and Clinical Immunology, February 2009, Elsevier

    Mr Aaron Yarlas

  51. Asymmetric Interference in Processing of Information Structure: Elements Interfere With Relations, but Not Vice Versa

    Article • January 2004, American Psychological Association (APA)

    Mr Aaron Yarlas

  52. Evidence for Parallel Processing of Elements and Relations

    Article • January 2002, American Psychological Association (APA)

    Mr Aaron Yarlas

  53. Processing of elements and relations: Is there a temporal order?

    Article • January 2001, American Psychological Association (APA)

    Mr Aaron Yarlas

  54. Effects of communication, information overlap, and behavioral consistency on consensus in social perception.

    Article • Journal of Personality and Social Psychology, January 1997, American Psychological Association (APA)

    Mr Aaron Yarlas

  55. Effects of communication, information overlap, and behavioral consistency on consensus in social perception.

    Article • Journal of Personality and Social Psychology, January 1997, American Psychological Association (APA)

    Mr Aaron Yarlas

  56. A Causal-Power Theory of Focal Sets

    Article • January 1996, Elsevier

    Mr Aaron Yarlas

  57. Agreement and accuracy in children's interpersonal perception: A social relations analysis.

    Article • Journal of Personality and Social Psychology, January 1996, American Psychological Association (APA)

    Mr Aaron Yarlas

  58. Agreement and accuracy in children's interpersonal perception: A social relations analysis.

    Article • Journal of Personality and Social Psychology, January 1996, American Psychological Association (APA)

    Mr Aaron Yarlas